Innate Pharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Innate Pharma Analyst Ratings
HC Wainwright & Co. : The Innate Pharma (IPHA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $11.50.
Innate Pharma SA: A Balanced Hold Rating Amidst Clinical Setbacks and Cautious Optimism
Analysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)
Innate Pharma Analyst Ratings
Innate Pharma SA (IPHYF) Receives a Hold From Kepler Capital
Analysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Innate Pharma SA (OtherIPHYF)
Promising Clinical Outcomes and Strategic Partnerships Reinforce Buy Rating for Innate Pharma
Analysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF) and Medios AG (OtherMEDOF)
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Innate Pharma Analyst Ratings
Promising Updates on Lacutamab and ANKET Portfolio Fuel Buy Rating for Innate Pharma's Stock
Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Innate Pharma (IPHA) and Shockwave Medical (SWAV)
Kepler Capital Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Innate Pharma Analyst Ratings
No Data